title: [Biologicals first-line in chronic inflammatory bowel disease? No].
authors: Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Robert-Bosch-Krankenhaus, Stuttgart
authors: K
authors: K
authors: Herrlinger
authors: E F
authors: EF
authors: Stange
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001379:Azathioprine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000191:economics; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005858:Germany; D006801:Humans; D000069285:Infliximab; D008134:Long-Term Care; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D015983:Selection Bias; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D001379:Azathioprine